The GEOLynch Cohort Study

Neoplasms Clinical Trial

— GEOLynch  

Official title:

The GEOLynch Cohort Study: Genetic, Environmental and Other Factors That Influence Tumour Risk Among Persons With Lynch Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03303833
• Other study ID #: CMO 2005-283
• Secondary ID: 2014/11842005-32
• Status: Recruiting
• Phase: N/A
• First received: September 14, 2017
• Last updated: October 5, 2017
• Start date: July 1, 2006
• Est. completion date: December 2030

Study information

• Verified date: October 2017
• Source: Wageningen University
• Contact: Fränzel van Duijnhoven, PhD
• Phone: +31 317 485 375
• Email: franzel.vanduijnhoven[@]wur.nl
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The GEOLynch cohort study has been established to investigate the influence of genetic, environmental and other factors on tumour risk in persons with Lynch syndrome.

Description:

The GEOLynch cohort study includes persons with Lynch syndrome (LS) only. Persons with LS carry an inherited mutation in one of the DNA mismatch repair genes MLH1, MSH2, MSH6 or PMS2 which increases their risk of several types of cancer, especially colorectal and endometrial cancer. Additionally, mutations in the EPCAM gene that result in epigenetic silencing of the MSH2 gene cause LS. Since 2006, persons with LS are invited to participate in the GEOLynch cohort study via the Netherlands Foundation for the Detection of Hereditary Tumours, the Radboud University Medical Center Nijmegen or the University Medical Centre Groningen. Moreover, persons with LS can participate in the study after contacting the researcher themselves. Participants are asked to complete a food frequency questionnaire and questionnaires about dietary supplement use, physical activity, weight, height and medication use. A buccal swab was asked of every participant recruited between 2006 and 2008. From 2012 on, newly recruited participants are asked to donate a blood sample instead of a buccal swab. Furthermore, participants who had been recruited between 2006 and 2008 were asked to complete the questionnaires again and to donate a blood sample too. Hence, follow-up measurements are available for a subset of participants. DNA has been subtracted from the buccal swabs to genotype SNPs of the IGF gene axis and polymorphisms of MTHFR C377T. Blood samples are biobanked to facilitate future analyses of biomarkers, nutrients, DNA etc. Clinical characteristics regarding performed colonoscopies and tumour diagnoses of all participants is gathered from medical records and a linkage to the nationwide network and registry of histo- and cytopathology in the Netherlands (PALGA Foundation ). Hazard ratios will be calculated to investigate the influence of genetic, environmental and other factor on tumour risk. Repeated measures analyses will be used if follow-up measurements are taken into account.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 2030
• Est. primary completion date: December 2030
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Persons with a known mutation in a gene that causes Lynch syndrome, i.e. with an inherited monoallelic pathogenic germline mutation in either the MLH1, MSH2, MSH6, PMS2 or EPCAM gene.

• Aged between 18 and 80 years at inclusion.

Exclusion Criteria:

• Additional carrier of another hereditary colon cancer predisposition syndrome (e.g. FAP)

• (Chronic) Inflammatory bowel disease

• Non-Dutch speaking

• Dementia or another mental condition that makes it impossible to fill out questionnaires

• Terminally ill persons

Related Conditions & MeSH terms

• Colorectal Neoplasms
• Colorectal Neoplasms, Hereditary Nonpolyposis
• Hereditary Nonpolyposis Colorectal Cancer
• Lynch Syndrome
• Neoplasms
• Syndrome

Intervention

Other:
• No intervention, observational study.

Locations

Country	Name	City	State
Netherlands	Wageningen University	Wageningen

Sponsors (4)

Lead Sponsor	Collaborator
Wageningen University	Funding: Biobanking and BioMolecular resources Research Infrastructure The Netherlands, Funding: Dutch Cancer Society, Funding: Wereld Kanker Onderzoek Fonds

Country where clinical trial is conducted

Netherlands, 

References & Publications (6)

Botma A, Nagengast FM, Braem MG, Hendriks JC, Kleibeuker JH, Vasen HF, Kampman E. Body mass index increases risk of colorectal adenomas in men with Lynch syndrome: the GEOLynch cohort study. J Clin Oncol. 2010 Oct 1;28(28):4346-53. doi: 10.1200/JCO.2010.2 — View Citation

Botma A, Vasen HF, van Duijnhoven FJ, Kleibeuker JH, Nagengast FM, Kampman E. Dietary patterns and colorectal adenomas in Lynch syndrome: the GEOLynch cohort study. Cancer. 2013 Feb 1;119(3):512-21. doi: 10.1002/cncr.27726. Epub 2012 Dec 17. Erratum in: C — View Citation

Heine-Bröring RC, Winkels RM, Botma A, van Duijnhoven FJ, Jung AY, Kleibeuker JH, Nagengast FM, Vasen HF, Kampman E. Dietary Supplement Use and Colorectal Adenoma Risk in Individuals with Lynch Syndrome: The GEOLynch Cohort Study. PLoS One. 2013 Jun 18;8( — View Citation

Jung AY, van Duijnhoven FJ, Nagengast FM, Botma A, Heine-Bröring RC, Kleibeuker JH, Vasen HF, Harryvan JL, Winkels RM, Kampman E. Dietary B vitamin and methionine intake and MTHFR C677T genotype on risk of colorectal tumors in Lynch syndrome: the GEOLynch — View Citation

van Duijnhoven FJ, Botma A, Winkels R, Nagengast FM, Vasen HF, Kampman E. Do lifestyle factors influence colorectal cancer risk in Lynch syndrome? Fam Cancer. 2013 Jun;12(2):285-93. doi: 10.1007/s10689-013-9645-8. Review. — View Citation

Winkels RM, Botma A, Van Duijnhoven FJ, Nagengast FM, Kleibeuker JH, Vasen HF, Kampman E. Smoking increases the risk for colorectal adenomas in patients with Lynch syndrome. Gastroenterology. 2012 Feb;142(2):241-7. doi: 10.1053/j.gastro.2011.10.033. Epub — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Colorectal tumour diagnoses	All diagnosed colorectal adenomas and carcinomas described in paticipants' medical reports and/or pathology reports.	Diagnoses before and after study inclusion will be assessed approximately every 2 years until study completion by regularly reviewing medical reports and/or pathology reports.
Primary	Endometrial cancer diagnoses	All diagnosed endometrial cancers described in participants' medical reports and/or pathology reports.	Diagnoses before and after study inclusion will be assessed approximately every 2 years until study completion by regularly reviewing medical reports and/or pathology reports.
Primary	Overall cancer diagnoses	All diagnosed cancer types described in participants' medical reports and/or pathology reports.	Diagnoses before and after study inclusion will be assessed approximately every 2 years until study completion by regularly reviewing medical reports and/or pathology reports.

External Links

•   GEOLynch website